Physician profile
Yaoming Gu
NPI 1265478184
$13,261.71
in general payments reported to CMS, 2019-2025
67 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $1,003 · 2021: $1,554 · 2022: $2,064 · 2023: $2,153 · 2024: $2,479 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,615 · Travel and Lodging: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,614.98 |
| Travel and Lodging | $810.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,582.67 | 2019-2025 | Xtampza, Belbuca |
| Si-Bone, INC. | $1,017.44 | 2019-2024 | |
| Abbvie INC. | $792.05 | 2021-2025 | |
| Vertos Medical, INC. | $738.26 | 2019-2024 | Mild Device Kit |
| Boston Scientific Corporation | $727.58 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Medtronic, INC. | $502.06 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $486.54 | 2019-2025 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $448.45 | 2019-2025 | Relistor |
| Pfizer INC. | $424.53 | 2019-2025 | |
| Averitas Pharma INC. | $400.67 | 2023-2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $381.42 | 2019-2021 | |
| Grt US Holding, INC. | $328.91 | 2021-2022 | |
| Medtronic USA, INC. | $310.32 | 2019 | |
| Mml US, INC. | $284.19 | 2025 | Reactiv8 |
| Mallinckrodt Hospital Products INC. | $283.87 | 2022-2024 | Acthar |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaoming Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.